IBS vs IBD: What Is the Difference?

The confusion between IBS vs IBD — irritable bowel syndrome versus inflammatory bowel disease — is one of the most common and consequential misunderstandings in digestive health. Both conditions cause abdominal pain, changes in bowel habit, urgency, and significant quality of life impairment. They share no common treatment and have fundamentally different implications for long-term health. IBS is a functional disorder with no structural damage; IBD is a structural, autoimmune inflammatory disease with serious complications and an increased cancer risk. Getting the distinction right matters — both for the person managing their condition and for the clinicians treating them.

If you’ve been diagnosed with irritable bowel syndrome and are wondering whether it could “turn into” something more serious, or if you’re trying to understand why your doctor ordered a stool calprotectin test, this guide covers the full picture — from the biology of each condition to the tests that tell them apart.

What Is IBS?

Irritable bowel syndrome (IBS) is a functional gastrointestinal condition — classified as a disorder of gut-brain interaction — characterised by recurring abdominal pain associated with changes in bowel habit, without any structural or inflammatory cause.

The key facts about IBS that distinguish it from IBD:

• A colonoscopy in someone with IBS shows normal gut tissue — no inflammation, no damage, no abnormalities visible to the camera or on biopsy
• IBS does not cause structural damage to the gut over time, regardless of symptom duration or severity
• IBS does not progress to IBD — this is one of the most commonly asked and most important clarifications in IBS diagnosis
• IBS does not increase the risk of colorectal cancer
• IBS does not cause blood in the stool, unintentional weight loss, or fever

IBS is the most common gastrointestinal condition seen in primary care, affecting approximately 10–15% of the global population. It is diagnosed by symptom criteria (Rome IV) after exclusion of structural causes, not by any positive test result. For a detailed breakdown of IBS symptoms and triggers, including the full range of physical, dietary, and psychological factors involved, see our dedicated guide.

What Is IBD?

Inflammatory bowel disease (IBD) is a collective term for two distinct chronic autoimmune inflammatory diseases of the gastrointestinal tract: ulcerative colitis (UC) and Crohn’s disease. Despite the shared name, they are different diseases with different anatomical distributions, different inflammatory patterns, and different clinical courses.

What both have in common is that they involve real, structural inflammation of the gut wall — visible on colonoscopy, confirmed on biopsy, detectable through blood and stool biomarkers, and capable of causing serious complications including intestinal obstruction, fistulas, abscesses, and colorectal cancer (particularly in long-standing ulcerative colitis).

IBD affects approximately 0.3% of the population — about 50 times less common than IBS, yet far more medically serious.

The underlying mechanism of IBD is autoimmune: a dysregulated immune response attacks the gut wall in genetically predisposed individuals, triggered by environmental factors including gut microbiome composition, antibiotic exposure, infections, diet, and smoking. IBD is a chronic, relapsing-remitting disease — people typically experience flares of active disease alternating with periods of remission.

Ulcerative Colitis vs Crohn’s Disease

Although both are classified as IBD, ulcerative colitis and Crohn’s disease are distinct conditions with different patterns of inflammation and different complications.

Ulcerative Colitis:

• Inflammation confined to the mucosa (innermost layer) of the colon and rectum
• Starts at the rectum and extends continuously upward — always involves the rectum
• Hallmark symptom: bloody diarrhoea, urgency, tenesmus (the urge to defecate without passing stool), abdominal cramping
• Complications: toxic megacolon (life-threatening dilation of the colon), increased colorectal cancer risk (especially after 8–10 years of extensive colitis)
• Surgery (colectomy) can cure UC — the disease is confined to the colon and rectum

Crohn’s Disease:

• Can affect any part of the GI tract from mouth to anus
• Transmural inflammation — affects the full thickness of the gut wall, not just the mucosa
• Characterised by skip lesions — areas of inflamed bowel separated by normal tissue (non-continuous pattern)
• Most commonly involves the terminal ileum (the last section of the small bowel) and right colon
• Symptoms: abdominal pain (often right lower quadrant), diarrhoea (may not be bloody when small bowel is primarily affected), weight loss, fatigue
• Complications: intestinal strictures (narrowing leading to obstruction), fistulas (abnormal channels between gut and adjacent structures), abscesses, perianal disease
• More than 50% of people with Crohn’s eventually require surgery — but surgery does not cure Crohn’s (the disease can recur at the surgical site or elsewhere)

Key Differences: IBS vs IBD

The single most important non-invasive test to differentiate IBS from IBD is stool calprotectin. A level below 50 µg/g strongly suggests a functional condition (IBS); a level above 150–200 µg/g indicates active gut inflammation and warrants colonoscopy to exclude IBD. This test is inexpensive, non-invasive, and widely available — it should be part of any IBS assessment where there is clinical uncertainty.

Overlapping Symptoms

The confusion between IBS and IBD is understandable because they share significant symptom overlap. Both conditions can cause:

• Abdominal pain and cramping
• Changes in stool frequency and consistency
• Urgency — the sudden compelling need to defecate
• Bloating and gas
• Fatigue (partly from sleep disruption, partly from the burden of managing chronic symptoms)
• Nausea
• Worsening with psychological stress

This overlap means that early IBD can initially present in a way that closely resembles IBS — particularly when blood in the stool is minimal or absent, as can occur in small bowel Crohn’s disease where inflammation is distant from the rectum. It also means that people with established IBD in remission may have ongoing symptoms that resemble IBS — sometimes called “post-IBD functional symptoms” or “IBS in IBD.”

Understanding how stress affects digestive symptoms is particularly relevant here — stress worsens both IBS and IBD, which is one reason psychological triggers cause confusion between the two conditions.

What distinguishes IBD from IBS within this overlapping zone:

• Blood in the stool — absent in IBS, common in UC (and possible in Crohn’s)
• Nocturnal symptoms — waking from sleep with pain or diarrhoea is unusual for IBS but characteristic of active IBD
• Weight loss — IBS does not cause weight loss; IBD active disease commonly does
• Systemic features — fever, joint pain, skin rash, eye inflammation suggest IBD
• Elevated stool calprotectin — the most reliable non-invasive differentiator

How Is Each Diagnosed?

IBS diagnosis: Clinical assessment of symptoms against Rome IV criteria, combined with basic tests to exclude structural mimics. There is no positive test that confirms IBS — diagnosis is based on symptom pattern plus reasonable exclusion of other causes. Standard tests include full blood count, CRP, coeliac serology (tTG-IgA), and stool calprotectin. Colonoscopy is only performed if alarm features are present.

IBD diagnosis: Cannot be made by symptoms alone — requires colonoscopy with biopsies for definitive diagnosis.

• Stool calprotectin is the most clinically useful non-invasive test: a result below 50 µg/g strongly suggests functional IBS; a result above 150–200 µg/g suggests active gut inflammation and warrants colonoscopy. This test allows appropriate triage without exposing low-risk patients to unnecessary invasive procedures. (Tibble et al., Gastroenterology 2000)
• CRP and ESR are elevated in active IBD and normal in IBS
• Colonoscopy with biopsies confirms the diagnosis, establishes disease extent (for UC), identifies complications (strictures, fistulas in Crohn’s), and allows cancer surveillance
• MRI enterography (MRI of the small bowel with contrast) is used to assess the extent and activity of small bowel Crohn’s disease, which colonoscopy cannot directly visualise

When to Suspect IBD Rather Than IBS

The following features should raise clinical concern for IBD rather than IBS and prompt investigation:

Strong concern for IBD — requires prompt investigation:

• Blood in stool (red, dark, or maroon)
• Nocturnal diarrhoea or pain waking from sleep
• Unintentional weight loss of more than 5% body weight
• Fever accompanying bowel symptoms
• Extra-intestinal symptoms: arthritis, skin rashes (erythema nodosum, pyoderma gangrenosum), eye inflammation (uveitis), mouth ulcers
• Family history of IBD in a first-degree relative

Moderate concern — warrants basic investigation:

• Stool calprotectin above 150 µg/g
• CRP or ESR elevated without an obvious alternative explanation
• Symptoms onset in a child or young adult — IBD incidence peaks between ages 15 and 35
• Symptoms refractory to standard IBS management despite good adherence to dietary and psychological approaches

The gut-brain connection plays an important role in both conditions. Understanding the gut-brain axis helps explain why psychological approaches are central to IBS treatment but not sufficient for active IBD.

Treatment: How They Differ

IBS treatment focuses on the gut-brain axis and digestive function:

• Low-FODMAP diet for dietary trigger management (elimination followed by structured reintroduction)
• Soluble fibre supplementation for IBS-C; reducing fat, caffeine, and alcohol for IBS-D
• Cognitive behavioural therapy (CBT) and gut-directed hypnotherapy — best evidence for durable improvement in IBS
• Peppermint oil and antispasmodics (hyoscine, mebeverine) for abdominal pain
• Low-dose tricyclic antidepressants for IBS-D and pain-predominant IBS
• Linaclotide, lubiprostone for IBS-C

IBD treatment targets the immune system and inflammation:

• Aminosalicylates (5-ASA): mesalazine — first-line for mild-moderate UC; anti-inflammatory, not immunosuppressive
• Corticosteroids: prednisolone, budesonide — for inducing remission in acute flares; not suitable for long-term maintenance due to side effects
• Immunosuppressants: azathioprine, 6-mercaptopurine — for maintaining remission and reducing steroid dependence
• Biologics: anti-TNF agents (infliximab, adalimumab), vedolizumab (gut-selective integrin inhibitor), ustekinumab (anti-IL-12/23) — for moderate-severe IBD not controlled by conventional therapy (Torres et al., Lancet 2017; Ungaro et al., Lancet 2017)
• Surgery: colectomy can cure UC (though with quality of life implications); surgery in Crohn’s removes complications but does not cure the disease

These treatment approaches are fundamentally distinct. Someone with IBD managed as IBS will receive no effective treatment for the underlying inflammation — potentially allowing the disease to progress and cause serious complications. Someone with IBS managed as IBD may be unnecessarily exposed to significant immunosuppression with its attendant risks.

Living With IBS vs IBD

Both IBS and IBD significantly affect quality of life, though for different reasons and through different mechanisms.

Common to both conditions:

• High rates of anxiety and depression — approximately 30–40% of treatment-seeking patients with either condition have a comorbid mood disorder
• Significant impact on work, social activities, travel, and personal relationships
• The unpredictability of symptoms is a major burden: not knowing when symptoms will strike limits participation in normal activities

Distinct burden in IBD:

• Fear of serious complications — obstruction, fistulas, perforation, requiring emergency surgery
• Cancer surveillance requirements: colonoscopy every 1–2 years after 8–10 years of extensive UC
• Surgery as a realistic prospect, particularly in Crohn’s disease where over 50% of patients eventually require surgery
• Long-term immunosuppression and its infection risk, monitoring requirements, and effects on fertility
• Nutritional complications from malabsorption, particularly in Crohn’s affecting the small bowel

Distinct burden in IBS:

• Feeling dismissed or disbelieved — “nothing is wrong on the tests” is a common and deeply frustrating experience
• Difficulty justifying absence from work or functional impairment without a visible, diagnosable structural disease
• Undertreated because the most effective interventions (psychological therapies) are poorly accessed — long waiting lists, costs, and stigma around “mental health treatment for a bowel condition” are common barriers

Both conditions benefit from specialist support. For IBD: gastroenterology with IBD nurse specialists who coordinate flare management, monitoring, and medication. For IBS: specialist dietitian for structured FODMAP guidance, and a GI psychologist or CBT therapist for gut-directed psychological work. (Ford AC et al., N Engl J Med 2017)

The Role of the Gut Microbiome in IBS and IBD

One of the most active areas of research in both IBS and IBD is the role of the gut microbiome — the complex community of bacteria, fungi, viruses, and other microorganisms that colonise the digestive tract. While the microbiome is implicated in both conditions, the mechanisms and degree of disruption differ substantially.

In IBD, gut microbiome dysbiosis is a core feature of the disease, not just a consequence. People with Crohn’s disease and ulcerative colitis consistently show reduced microbial diversity — fewer distinct species — and a relative depletion of key anti-inflammatory bacteria such as Faecalibacterium prausnitzii and Roseburia intestinalis. These bacteria produce short-chain fatty acids (particularly butyrate) that nourish the gut lining and regulate immune function. Their absence creates a pro-inflammatory environment that perpetuates mucosal damage. This is why fecal microbiota transplantation (FMT) has shown promise in ulcerative colitis — restoring a healthier microbial community can induce remission in a subset of patients, and randomised trials have shown remission rates of 30–35% with FMT versus 5–9% with placebo in active UC.

In IBS, the microbiome picture is less clearly defined but increasingly recognised as clinically relevant. Post-infectious IBS — which develops in approximately 10% of people following an acute gastrointestinal infection — provides the clearest evidence: the infecting pathogen disrupts the microbiome, and this dysbiosis appears to persist even after the infection clears, driving ongoing functional gut symptoms through altered gut motility, visceral hypersensitivity, and low-grade immune activation. Beyond post-infectious IBS, studies show that IBS patients as a group have lower levels of Bifidobacterium and Lactobacillus species compared to healthy controls, though the clinical significance of specific microbiome signatures in IBS remains an active area of investigation.

The microbiome finding with the clearest practical implication for distinguishing IBS from IBD concerns stool calprotectin: calprotectin is released by neutrophils recruited to the gut wall during active inflammation — a process that occurs in IBD but not in the functional gut barrier disruption seen in IBS. This is why calprotectin remains the most useful non-invasive discriminating test.

IBS and IBD in Children and Young Adults

Both IBS and IBD can affect children and adolescents, though their presentations and implications differ in this age group. IBD in particular carries unique concerns in paediatric patients, and early diagnosis is essential to prevent growth failure and pubertal delay caused by untreated intestinal inflammation and malnutrition.

Paediatric IBD often presents more extensively than adult-onset disease — pan-colitis (inflammation of the entire colon) is more common in paediatric UC, and Crohn’s disease with upper GI involvement (stomach, small bowel) is more frequent in children. Exclusive enteral nutrition (EEN) — a liquid-only formula diet — is first-line induction therapy for paediatric Crohn’s disease, replacing corticosteroids as the preferred approach because it promotes mucosal healing while supporting nutrition and growth.

IBS in adolescents is common and frequently under-recognised. Recurrent abdominal pain affects approximately 10–15% of school-age children and adolescents, and a significant proportion meets Rome IV criteria for IBS. The gut-brain axis is particularly active during adolescence, and the bidirectional relationship between academic stress, anxiety, and gut symptoms is often prominent. Gut-directed hypnotherapy has strong evidence in paediatric IBS, with response rates of 70–85% in randomised trials — higher than in adult IBS.

The key practical point: IBD incidence peaks in the 15–35 age group, which means a teenager or young adult presenting with what looks like IBS should have basic inflammatory markers (CRP and stool calprotectin) checked. A normal calprotectin in a symptomatic young adult provides strong reassurance that IBD is not the cause; an elevated calprotectin warrants prompt gastroenterology referral.

Frequently Asked Questions

---

This article is for educational purposes only and does not constitute medical advice. Anyone experiencing blood in the stool, unintentional weight loss, nocturnal symptoms, or other alarm features should seek prompt medical evaluation.

References:
1. Ford AC et al. Irritable bowel syndrome. N Engl J Med. 2017;376(26):2566–78.
2. Torres J et al. Crohn’s disease. Lancet. 2017;389(10080):1741–55.
3. Ungaro R et al. Ulcerative colitis. Lancet. 2017;389(10080):1756–70.
4. Tibble JA et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119(1):15–22.